Low-dose ATG in combination with PTCy in alloHSCT & biomarkers for GvHD

Low-dose ATG in combination with PTCy in alloHSCT & biomarkers for GvHDПодробнее

ATG vs PTCy as GvHD prophylaxis in non-myeloablative MUD alloHSCTПодробнее

When would you use ATG vs PTCy for GvHD prophylaxis?Подробнее

Can adding ATG to PTCy further reduce the risk of GvHD?Подробнее

Is it possible to efficiently prevent GvHD with a modified PTCy dosing schedule?Подробнее

Is combination ATG + PTCy prophylaxis always preferable to using each agent separately in haplo-HCT?Подробнее

PTCy vs ATG for GvHD prophylaxis in MUD and MMUD transplantationПодробнее

GvHD prophylaxis: PTCY vs ATG in AML with allo-HSCTПодробнее

PTCy vs ATG in ALL in haploidentical, unrelated and sibling donor transplantationПодробнее

Should we use PTCy or ATG as GvHD prophylaxis in haploidentical stem cell transplantation?Подробнее

PTCy/Tac/MMF as the new standard for GVHD prophylaxis in reduced intensity conditioningПодробнее

The role of PTCy/MMF/CNI as the standard of care for GvHD prophylaxis in the MUD settingПодробнее

Cord blood transplantation vs MMUD with PTCy in AMLПодробнее

PTCy/Tac/MMF gives a higher 1-year GVHD/relapse or PFS compared to Tac/MTX in GVHDПодробнее

ATG and/or post-Cy for GvHD prophylaxisПодробнее

Latest advances in GvHD prophylaxis: TAC/MMF/PTCy & abataceptПодробнее

Post-transplant cyclophosphamide versus standard GvHD prophylaxis after alloSCT for AML & MDSПодробнее

Factors determining the effectiveness of treatment with ATG following transplantationПодробнее

Adding ATG to post-transplantation cyclophosphamideПодробнее

PTCy versus ATG as haploidentical transplant prophylaxisПодробнее